Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
Community Health Systems posts $0.19 per-share loss, missing Q2 estimates
Edgen Stock·Jul 23 2026, 18:01Share to
Share to
Copy link
Related News
Jul 23 2026, 19:49
Applied Digital faces Q4 test as $16B lease backlog grows
Applied Digital reports fiscal Q4 earnings Wednesday with $16 billion in signed hyperscaler leases backing its AI data center buildout, though investors will scrutinize whether revenue growth is translating into sustainable profitability. "The company has REIT-grade cash flow visibility attached to a roughly 1 GW pipeline," Benchmark analyst Josh Sullivan, who rates APLD a buy with a $76.70 target, said. Revenue reached $126.64 million in the fiscal third quarter, up 139.3% year over year, while adjusted EBITDA jumped to $44.14 million from $6.26 million a year earlier. Adjusted EPS of $0.09 beat the -$0.21 consensus, marking the fourth straight earnings beat. The company holds $1.73 billion in cash and recently raised $2.15 billion in senior secured notes at 6.750% to fund the Polaris Forge 2 expansion. The 400 MW Polaris Forge 1 is fully contracted to CoreWeave for roughly $11 billion in total revenue, and a 200 MW lease with an investment-grade hyperscaler adds another $5 billion over its term. Management targets $1 billion in net operating income within five years — a threshold that would validate the data center landlord model for AI infrastructure. **Why APLD Stands Apart From the AI Infrastructure Peer Set** The natural comparison is IREN, the other pure-play AI data center operator transitioning from Bitcoin mining. IREN posted 0% quarterly revenue growth year over year at its last report against APLD's 139.3%. Over the past 12 months, APLD returned 174.7% versus IREN's 122.05%. The difference comes down to contract structure: APLD's revenue is backed by long-duration hyperscaler leases, not GPU spot pricing. Nvidia's $3 billion investment in under-the-radar tech stocks, disclosed in a recent filing, has also drawn attention to the AI infrastructure supply chain. While APLD was not among Nvidia's disclosed holdings, the broader trend of hyperscaler and chipmaker capital flowing into data center capacity supports the thesis that demand for AI compute will remain elevated through 2027. CoreWeave, APLD's largest tenant, has itself benefited from this dynamic, securing Nvidia GPU allocations that underpin its own cloud services business. **The Profitability Question** GAAP losses remain real. The company's CoreWeave concentration — Polaris Forge 1 represents roughly 69% of total contracted revenue — is a risk if that customer's own business model faces pressure. CoreWeave recently hit profitability, according to its latest earnings, but insider selling at the cloud provider has raised questions about management conviction. APLD has begun diversifying. The Polaris Forge 2 lease with an investment-grade hyperscaler reduces single-customer dependency. Insiders have logged 12 recent buy transactions, showing confidence from those closest to the numbers. With $1.73 billion in cash and a 6.750% cost of capital on its latest debt offering, the company has the runway to complete its current buildout without equity dilution. For investors, the Q4 report will answer whether the revenue trajectory is accelerating or decelerating. The 11 analysts covering APLD rate it a buy with zero holds or sells, and the consensus price target of $76.70 implies 155% upside from the current $30.08. If management delivers another beat and maintains its $1 billion NOI target, the stock could re-rate closer to data center REIT multiples rather than speculative growth stock valuations. APLD currently trades at roughly 6.5x forward revenue, a discount to data center REITs like Equinix at 9x, reflecting the profitability discount the market is demanding. This article is for informational purposes only and does not constitute investment advice.
Jul 23 2026, 19:46
Freeport-McMoRan beats Q2 estimates as copper prices offset volume declines
Freeport-McMoRan reported second-quarter adjusted earnings of 74 cents a share, beating the 62-cent consensus by 19.4%, as higher realized metal prices offset steep declines in copper and gold production. Revenue of $7.03 billion surpassed the $6.47 billion consensus estimate, though it fell 7.3% from $7.58 billion a year earlier. Net income rose to $984 million, or 68 cents a share, from $772 million, or 53 cents, in the year-ago period. "The strong financial results reflect the benefit of higher copper and gold prices, which more than offset lower sales volumes as we continue the ramp-up at Grasberg Block Cave," the company said in its earnings release. Copper sales dropped 30.1% year over year to 710 million pounds, while gold sales plunged 76.4% to 123,000 ounces, reflecting lower operating rates at PT Freeport Indonesia during the phased ramp-up of the Grasberg Block Cave underground mine following the mud rush incident in September 2025. Molybdenum sales rose 13.6% to 25 million pounds. The average realized copper price climbed 35.9% to $6.17 a pound, and the average realized gold price rose 37.3% to $4,520 an ounce. Unit net cash costs surged 74.3% to $1.97 a pound, driven by higher energy and consumable costs tied to the Middle East conflict and persistent pressure on volumes. Cash flow from operations totaled $2 billion in the quarter, down 6.7% from a year earlier. Capital expenditures fell to $1.1 billion from $1.26 billion. The company ended the quarter with $4.1 billion in cash and $9.4 billion in total debt. For the full year, Freeport maintained its copper sales guidance at 3.1 billion pounds, with gold sales of 650,000 ounces and molybdenum sales of 93 million pounds. Third-quarter copper sales are projected at 750 million pounds, with gold sales of 160,000 ounces. Shares of Freeport-McMoRan have gained 28% since the start of the year, outperforming the S&P 500's 9.6% advance. The stock carries a Zacks Rank of 3 (Hold), reflecting mixed estimate revision trends ahead of the report. The earnings beat signals that copper miners can still deliver margin expansion even amid production constraints, as structural demand from electrification, renewable energy and data centers keeps prices elevated. Investors will watch third-quarter results for further progress on the Grasberg ramp-up and updated cost guidance. This article is for informational purposes only and does not constitute investment advice.
Jul 23 2026, 19:43
Pfizer's Talzenna combo cuts prostate cancer risk 52%, wins FDA priority review
Pfizer Inc. said the FDA granted priority review to its Talzenna (talazoparib) plus Xtandi (enzalutamide) combination for men with HRR gene-mutated metastatic castration-sensitive prostate cancer, setting a PDUFA action date in the final quarter of 2026. "Intervening during the hormone-sensitive stage represents an important opportunity to delay progression before the disease becomes more difficult to manage," Jeff Legos, chief oncology officer at Pfizer, said in a statement. The supplemental application is backed by the Phase 3 TALAPRO-3 trial, which enrolled 599 patients and showed the combination reduced the risk of radiographic progression or death by 52% versus placebo plus Xtandi. The benefit was consistent across patients with BRCA and non-BRCA HRR gene alterations, according to results presented at the 2026 American Society of Clinical Oncology annual meeting and published simultaneously in the New England Journal of Medicine. The safety profile matched the known profiles of each agent, with no new safety signals identified. An expanded approval would allow Pfizer to move the combination into an earlier disease stage. The drug pair is currently approved in the US for HRR gene-mutated metastatic castration-resistant prostate cancer, a later-stage indication, and is authorized in more than 60 countries for that use. Metastatic castration-sensitive prostate cancer accounts for 5% to 10% of newly diagnosed cases, and up to 30% of those patients harbor HRR gene alterations, according to Pfizer. The combination is also under review by the European Medicines Agency for the same indication. The priority review designation shortens the FDA's standard 10-month review to about six months, accelerating a potential label expansion that could broaden the addressable patient population for Talzenna. Pfizer did not disclose a peak sales estimate for the expanded indication. Investors will watch the PDUFA date in the fourth quarter for the final regulatory decision. This article is for informational purposes only and does not constitute investment advice.